[go: up one dir, main page]

CA2709950A1 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
CA2709950A1
CA2709950A1 CA2709950A CA2709950A CA2709950A1 CA 2709950 A1 CA2709950 A1 CA 2709950A1 CA 2709950 A CA2709950 A CA 2709950A CA 2709950 A CA2709950 A CA 2709950A CA 2709950 A1 CA2709950 A1 CA 2709950A1
Authority
CA
Canada
Prior art keywords
antagonist
release
pain
naltrexone
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709950A
Other languages
English (en)
Inventor
Alfred Liang
Frank Matthews
Garth Boehm
Lijuan Tang
Frank Johnson
Joseph Stauffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpharma Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709950A1 publication Critical patent/CA2709950A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2709950A 2007-12-17 2008-12-16 Compositions pharmaceutiques Abandoned CA2709950A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US793507P 2007-12-17 2007-12-17
US61/007,935 2007-12-17
PCT/US2008/087043 WO2009085778A1 (fr) 2007-12-17 2008-12-16 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
CA2709950A1 true CA2709950A1 (fr) 2009-07-09

Family

ID=40824650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709950A Abandoned CA2709950A1 (fr) 2007-12-17 2008-12-16 Compositions pharmaceutiques

Country Status (4)

Country Link
EP (1) EP2224915A4 (fr)
AU (1) AU2008343267A1 (fr)
CA (1) CA2709950A1 (fr)
WO (1) WO2009085778A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (fr) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Compositions a liberation regulee contenant des agonistes et antagonistes de l'opioide
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2009088673A2 (fr) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Composition pharmaceutique
EP2224806A4 (fr) * 2007-12-17 2014-02-19 Alpharma Pharmaceuticals Llc Composition pharmaceutique
JP2012087101A (ja) * 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
US9456986B2 (en) 2013-12-11 2016-10-04 Develco Pharma Schweiz Ag Naloxone mono preparation and multilayer tablet

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0914097T3 (da) * 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
WO2001058447A1 (fr) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Compositions a liberation regulee contenant des agonistes et antagonistes de l'opioide
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
CA2548834C (fr) * 2003-12-09 2009-08-11 Euro-Celtique S.A. Forme posologique co-extrudee inviolable contenant un principe actif et un principe contraire, et procede de fabrication
PT2484346T (pt) * 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
WO2008027442A2 (fr) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Formulations pharmaceutiques orales anti-abus à base d'opioïdes et procédé d'utilisation
EP2073797A2 (fr) * 2006-10-11 2009-07-01 Alpharma, Inc. Compositions pharmaceutiques
US20090131466A1 (en) * 2007-09-04 2009-05-21 Alpharma, Inc. Pharmaceutical Compositions
WO2009088673A2 (fr) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Composition pharmaceutique
EP2224806A4 (fr) * 2007-12-17 2014-02-19 Alpharma Pharmaceuticals Llc Composition pharmaceutique

Also Published As

Publication number Publication date
WO2009085778A1 (fr) 2009-07-09
AU2008343267A1 (en) 2009-07-09
EP2224915A1 (fr) 2010-09-08
EP2224915A4 (fr) 2014-01-22

Similar Documents

Publication Publication Date Title
US8623418B2 (en) Pharmaceutical composition
US20140037721A1 (en) Pharmaceutical Composition
CA2709950A1 (fr) Compositions pharmaceutiques
CA2714921C (fr) Compositions pharmaceutiques
CA2665726C (fr) Compositions pharmaceutiques
EP2719378A1 (fr) Compositions pharmaceutiques
US20150104519A1 (en) Pharmaceutical Compositions
AU2008338439A1 (en) Pharmaceutical composition
AU2014216032B2 (en) Pharmaceutical composition
AU2019202760A1 (en) Pharmaceutical composition
AU2018202217A1 (en) Pharmaceutical composition
AU2014250614B2 (en) A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
AU2015200402A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition
AU2016201136A1 (en) Pharmaceutical compositions
AU2013211445A1 (en) Pharmaceutical Compositions
HK1176867A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20180724